<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135499</url>
  </required_header>
  <id_info>
    <org_study_id>LNH01-5B</org_study_id>
    <nct_id>NCT00135499</nct_id>
  </id_info>
  <brief_title>R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Non Previously Treated Patients Aged From 60 to 65 Years With Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation ARC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lymphoma Study Association</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of doxorubicin,
      cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) plus rituximab in comparison
      to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) plus rituximab in patients
      aged from 60 to 65 years with non-previously treated diffuse large B-cell lymphoma as
      measured by the event-free survival. The goal is to obtain a 10% increase of event-free
      survival at 3 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Europe, 50% or more of new non-Hodgkin lymphoma cases occur in patients older than 60
      years. More than 30% are diffuse large B-cell lymphomas (DLCL).

      The CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) was considered
      as the standard treatment in this population. Nevertheless, this treatment is associated with
      some toxic events in elderly patients and it did does not succeed to increase the 3-year
      survival rate above 40%.

      Two trials in patients above 60 years with DLCL cases were conducted by the GELA in the aim
      to improve the results of CHOP.

      Protocol LNH 93-5 : The primary objective of this study was to compare CHOP to ACVBP in
      patients aged from 61 to 69 years with aggressive lymphoma and at least one adverse
      prognostic factor according to the International Prognostic Index.

      Unlike the CHOP regimen, the ACVBP regimen includes a more intensive induction followed by a
      sequential consolidation with drugs different from those used during the induction phase, and
      includes a prevention of neuromeningeal relapses.

      Out of 708 patients included in this study, the results have shown that:

        -  Complete response rate was the same in the two arms.

        -  Event free survival was significantly better in the ACVBP arm than the CHOP arm ( 5-year
           survival rate : 39% versus 29%, p=0.005).

        -  Overall survival was significantly better in the ACVBP arm than in the CHOP arm (the
           5-year survival rate : 46% versus 38%, p=0.036).

        -  The ACVBP regimen was more toxic than the CHOP regimen, particularly in elderly patients
           (&gt; 65 years) and in patients with a low performance status.

        -  Prevention of neuromeningeal relapses was necessary for these patients.

      Protocol LNH 98-5, the objective of this study was to compare the association CHOP +
      rituximab (R-CHOP) to the CHOP regimen alone in elderly patients with non previously treated
      diffuse large B-cell lymphoma.

      Long-term results based on data from 399 patients, with a median follow-up of 5 years were as
      follows :

        -  Complete response rate was better in the R-CHOP arm than in the CHOP arm (76% versus
           61%, p&lt;0.005).

        -  Significant prolongation of event-free survival (p&lt;0.0002) and overall survival
           (p&lt;0.0073) in the R-CHOP arm.

        -  No significant difference between the two arms in terms of toxicity. R-CHOP is now
           considered worldwide as the standard combination for these patients.

      These conclusions invited us to propose a randomized trial comparing ACVBP + rituximab to
      CHOP + rituximab. The study population is limited to patients aged from 60 to 65 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment too low
  </why_stopped>
  <start_date type="Actual">October 16, 2001</start_date>
  <completion_date type="Actual">April 27, 2010</completion_date>
  <primary_completion_date type="Actual">April 27, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>event free survival</measure>
    <time_frame>8 years (end of study)</time_frame>
    <description>percentage of patients alive with no event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete response rate</measure>
    <time_frame>8 years (end of study)</time_frame>
    <description>percentage of patients with complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression rate</measure>
    <time_frame>8 years (end of study)</time_frame>
    <description>percentage of patients with progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse rate</measure>
    <time_frame>8 years (end of study)</time_frame>
    <description>percentage of patients with relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival for complete responders</measure>
    <time_frame>8 years (end of study)</time_frame>
    <description>percentage of patients with complete response who remain disease-free</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>8 years (end of study)</time_frame>
    <description>percentage of patients alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neuromeningeal relapse rate</measure>
    <time_frame>8 years (end of study)</time_frame>
    <description>percentage of patients with neuromeningeal relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of SAE</measure>
    <time_frame>8 years (end of study)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Lymphoma, Large-Cell, Diffuse</condition>
  <arm_group>
    <arm_group_label>R-ACVBP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-CHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rituximab, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m², D1, 4 cycles</description>
    <arm_group_label>R-ACVBP</arm_group_label>
    <arm_group_label>R-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>75 mg/m², D1, 4 cycles</description>
    <arm_group_label>R-ACVBP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>1200 mg/m², D1, 4 cycles</description>
    <arm_group_label>R-ACVBP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vindesine</intervention_name>
    <description>2 mg/m², D1, D5, 4 cycles</description>
    <arm_group_label>R-ACVBP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <description>10 mg, D1, D5, 4 cycles</description>
    <arm_group_label>R-ACVBP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>60 mg, D1-D5, 4 cycles</description>
    <arm_group_label>R-ACVBP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>40 mg, D1-D5, 4 cycles</description>
    <arm_group_label>R-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50 mg/m², D1, 4 cycles</description>
    <arm_group_label>R-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750 mg/m², D1, 4 cycles</description>
    <arm_group_label>R-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.4 mg/m², D1, 4 cycles</description>
    <arm_group_label>R-CHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with diffuse large B-cell lymphoma according to the WHO classification (anti
             CD20 labeling)

          -  Aged from 60 to 65 years.

          -  Not previously treated.

          -  Ann Arbor stage II, III, IV.

          -  ECOG performance status 0 to 2.

          -  Minimum life expectancy of 3 months.

          -  Negative HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies test 4
             weeks (except after vaccination).

          -  Having previously signed a written informed consent.

        Exclusion Criteria:

          -  T-cell lymphoma.

          -  Any history of treated or non-treated indolent lymphoma. However, patients not
             previously diagnosed and having a diffuse large B-cell lymphoma with some small cell
             infiltration in bone marrow or lymph node may be included.

          -  Central nervous system or meningeal involvement by lymphoma.

          -  Contra-indication to any drug contained in the chemotherapy regimens.

          -  Any serious active disease (according to the investigator's decision).

          -  Poor renal function (creatinine level&gt;150micromol/l), poor hepatic function (total
             bilirubin level&gt;30mmol/l, transaminases&gt;2.5 maximum normal level) unless these
             abnormalities are related to the lymphoma.

          -  Poor bone marrow reserve as defined by neutrophils&lt;1.5G/l or platelets&lt;100G/l, unless
             related to bone marrow infiltration.

          -  Any history of cancer during the last 5 years with the exception of non-melanoma skin
             tumors or stage 0 (in situ) cervical carcinoma.

          -  Treatment with any investigational drug within 30 days before planned first cycle of
             chemotherapy and during the study.

          -  Adult patient under tutelage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herve Tilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe d'Etude des Lymphomes de l'adulte</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie - Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schweirische Arbeitsgruppe fur klinische Krebsforschung</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.gela.org</url>
    <description>Official site of the Groupe d'Etudes des Lymphomes de l'Adulte (In french)</description>
  </link>
  <reference>
    <citation>Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003 Dec 15;102(13):4284-9. Epub 2003 Aug 14.</citation>
    <PMID>12920037</PMID>
  </reference>
  <reference>
    <citation>Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235-42.</citation>
    <PMID>11807147</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2005</study_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Vindesine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

